A9730
Adefovir dipivoxil
别名:
9-(2[bis(Pivaloyloxymethoxy)phosphorylmethoxy]ethyl)adenine
登录查看公司和协议定价
选择尺寸
关于此项目
经验公式（希尔记法）:
C20H32N5O8P
化学文摘社编号:
分子量:
501.47
MDL编号:
UNSPSC代码:
51102829
PubChem化学物质编号:
NACRES:
NA.76
生物来源
synthetic
质量水平
方案
≥98% (HPLC)
表单
powder
溶解性
ethanol: 50 mg/mL
抗生素抗菌谱
viruses
作用机制
enzyme | inhibits
储存温度
−20°C
SMILES字符串
CC(C)(C)C(=O)OCOP(=O)(COCCn1cnc2c(N)ncnc12)OCOC(=O)C(C)(C)C
InChI
1S/C20H32N5O8P/c1-19(2,3)17(26)30-11-32-34(28,33-12-31-18(27)20(4,5)6)13-29-8-7-25-10-24-14-15(21)22-9-23-16(14)25/h9-10H,7-8,11-13H2,1-6H3,(H2,21,22,23)
InChI key
WOZSCQDILHKSGG-UHFFFAOYSA-N
生化/生理作用
Adefovir is an antiviral acyclic nucleoside phosphonate (ANP) analog that works by blocking reverse transcriptase. It is an inhibitor of duck hepatitis B virus (DHBV) replication that inhibits covalently closed circular DNA (CCC DNA) amplification. Cytotxicity is induced by Human Renal Organic Anion Transporter 1 (hOAT1). Adefovir is an Inhibitor of edema factor (EF)-induced cAMP accumulation and changes in cytokine production in mouse primary macrophages .
其他说明
Keep container tightly closed in a dry and well-ventilated place.
警示用语：
Warning
危险分类
Acute Tox. 4 Oral
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
个人防护装备
dust mask type N95 (US), Eyeshields, Gloves
Man-Fung Yuen et al.
Expert opinion on pharmacotherapy, 5(11), 2361-2367 (2004-10-27)
Adefovir dipivoxil, an acyclic nucleotide analogue, is effective for the treatment of chronic hepatitis B in both hepatitis B e antigen (HBeAg)-positive and -negative patients, with improvement in liver histology, hepatitis B virus (HBV) DNA levels, alanine aminotransferase levels, and
Myron J Tong et al.
Seminars in liver disease, 24 Suppl 1, 37-44 (2004-06-12)
Adefovir dipivoxil, a nucleotide analog of adenosine monophosphate, is an antiviral agent that suppresses hepatitis B virus (HBV) replication through inhibition of DNA polymerase and by chain termination. To determine the effectiveness of adefovir, three populations of patients with chronic
Xiaokun Shen et al.
Scientific reports, 6, 38778-38778 (2016-12-13)
A pressing need exists for improved therapeutic options for chronic hepatitis B (CHB). Pegylated-interferon-alpha (Peg-IFN-α) achieves sustained off-treatment responses in many cases because of its direct anti-viral effects and regulation of the immune response. However, non-responsiveness to Peg-IFN-α is frequent
J Jones et al.
Health technology assessment (Winchester, England), 13(35), 1-172 (2009-07-18)
To update and extend a 2006 report on the clinical effectiveness and cost-effectiveness of adefovir dipivoxil (ADV) and pegylated interferon alpha (PEG-alpha) for the treatment of chronic hepatitis B (CHB). Thirteen bibliographic databases were searched including MEDLINE, EMBASE and the
Patrick Marcellin et al.
The New England journal of medicine, 348(9), 808-816 (2003-02-28)
In preclinical and phase 2 studies, adefovir dipivoxil demonstrated potent activity against hepatitis B virus (HBV), including lamivudine-resistant strains. We randomly assigned 515 patients with chronic hepatitis B who were positive for hepatitis B e antigen (HBeAg) to receive 10
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持